(RECEIVED FOR PUBLICATION MAY 25, 1959) The frequent occurrence of protein anomalies in patients with myelomatosis has long been recognized. Bence Jones reported on the unusual urinary protein of a patient with this disease over a hundred years ago (Bence Jones, 1848) . Hyperproteinaemia in myelomatosis was recorded somewhat later (Ellinger, 1899) . Subsequently, electrophoretic studies have shown that the hyperproteinaemia is due to the presence in serum of a protein or proteins apparently absent from normal serum.
In the past decade, however, it has become increasingly evident that anomalous protein components in serum or urine are not restricted to myelomatosis but occur in various other conditions. Such components have been the subject of many investigations, and it is the aim of this review to summarize current views on the nature and significance of these proteins.
Occurrence of Anomalous Serum Owen and Rider, 1957) . Lymphoma (using this as a generic term to include conditions designated more precisely lymphosarcoma, reticulum cell sarcoma, or Hodgkin's disease) is less frequently associated with anomalous serum components, although many instances have been recorded (e.g., Mackay, Taft, and Woods, 1957; Azar, Hill, and Osserman, 1957; Quattrin, Dini, and Piccoli, 1956; Mackay, 1959) .* Bence Jones proteinuria also occurs in lymphoma, though it is less common than anomalous serum components (Mandema, van der Schaaf, and Huisman, 1955: Jim and Steinkamp, 1956; Mackay et al., 1957) . Some patients with anomalous serum proteins present clinical and histological features intermediate between those of myelomatosis and malignant lymphoma (Mandema, 1954; Osserman and Gellhorn, 1955; Regniers, Wieme, Wunderly. and Burtin, 1956; Azar et al., 1957;  Motulsky. Eriksen, Volwiler, and Donohue, 1958; Owen, Pitney, and O'Dea, 1959) . Indeed the two conditions appear very closely related.
Occasionally, anomalous serum components monocytic leukaemia (Brown, Read, Wiseman, and France, 1948) , and in chronic myeloid leukaemia (Brown et al., 1948) . Such components have also been found in patients with myelofibrosis (Lucey, Leigh, Hoch, Marrack, Johns, Kekwick, and Holiday, 1950; Videbaek, 1955; Owen et al., 1959) though there was evidence in these cases of concomitant myelomatosis or lymphoma.
In a few instances anomalous serum components have been found in patients with malignant tumours in various sites (Schaub, 1953; Kanzow, 1954; Laurell, Laurell, and Waldenstrom, 1957; Waldenstrom, 1958; Kappeler, Krebs, and Riva, 1958; Owen et al., 1959) . However, in some, but not all, of these cases there was evidence of a co-existing lymphoma. Bence Jones proteinuria has been found in cases of bronchial carcinoma (Copeland, 1931; Hughes, 1954) .
MIiopathic Haemolytic Disease.-Christenson and Dacie (1957) have noted the frequent association of anomalous serum electrophoretic components in patients with idiopathic haemolytic anaemia of the cold-agglutinin type, and similar cases have been reported by others (Sonnet, Louis, and Heremans, 1955; Fudenberg and Kunkel, 1957; Fudenberg, Barry, and Dameshek, 1958; Owen et al., 1959) . The association of anomalous serum components with haemolytic anaemia has also been found in patients with lymphoma (Craig, Waterhouse, and Young, 1952; Buffa and Rappaport, 1957; Christenson and Dacie, 1957) . In contrast, anomalous serum components were not found in haemolytic anaemia of the warmagglutinin type (Christenson and Dacie, 1957; Charbonnier and Dausset, 1953) .
Miscellaneous.-There are a few isolated reports of anomalous serum components in various other conditions. Of particular interest is the finding (Laurell et al., 1957) of such a component in the serum of a blood donor who showed no other physical or laboratory signs of disease. Other reports have concerned patients* with obscure anaemia (Flynn, 1954; Pitney, O'Sullivan, and Owen, 1958) ; hepatitis (Wieme, 1953) ; chronic urticaria (Motulsky et al., 1958) ; granulomatous lung disease (Motulsky et al., 1958) ; and cases in which a definite diagnosis was not established (Martin and Close, 1957; Laurell et al., 1957; Waldenstr6m, 1958; Owen et al., 1959) . To be included in this group are some *It should be noted that in some of these cases the possibility of coincidental neoplasia, e.g., of the reticulo-endothelial system, was not rigorously excluded.
cases of " essential " cryoglobulinaemia (Hutchinson and Howell, 1953; Mackay, Eriksen, Motulsky, and Volwiler, 1956; Volp4, BruceRobertson, Fletcher, and Charles, 1956; Barnett, Curtain, and Hayes, 1956; Powers, 1958) .
Apart from the above, a number of instances of minor electrophoretic anomalies of the same type have been described. These reports have concerned patients with nephritis (Stern, Mais, and Boggs, 1957) , primary amyloidosis (Block, Rukavina, and Curtis, 1956) , rheumatic disease (Wallis, 1950; McQueen, O'Shea, and Summerfield, 1954; Salt, 1956) , tuberculosis (Matsui and Tamura, 1955) , and viral hepatitis (Wajchenberg and Hoxter, 1955) . However, others (for references see Owen, 1958a) (Putnam and Udin, 1953) . Anomalous components associated with acquired haemolytic disease show less variation in electrophoretic mobility (Fudenberg and Kunkel, 1957) (Slater, 1955) . In occasional cases, two or more electrophoretically distinct anomalous components were present in the serum (Knedel, 1955; Neely and Neill, 1956; Owen, Rider, and Stewart, 1956; Petermann, Hamilton, and Korngold, 1956; Tsevrenis and Samios, 1958) . Similar evidence has been obtained on electrophoresis of myeloma proteins in starch gel (Owen, Got, and Silberman, 1958) .
On examination with the ultracentrifuge, some anomalous components behave as if homogeneous, whilst others show heterogeneity even though they appear homogeneous on electrophoresis. Such heterogeneity, however, usually amounts to the presence of a main component with much smaller amounts of other components. In myelomatosis, the main or only component usually has a molecular weight (as indicated by the sedimentation constant*) approximately that of the bulk of normal y globulin (sedimentation constant S -=6-7 S). In contrast, the anomalous serum components in patients with lymphoma are commonly macroglobulins with higher molecular weights (S2= 11-28 S). However, these findings are not invariable. Thus, anomalous serum components with high sedimentation constants have been noted in patients with myelomatosis (Putnam and Udin, 1953; Smith, Brown, McFadden, Buettner-Janusch, and Jager, 1955; Motulsky et al., 1958; Wanner and Siebenmann, 1957; Curtain, 1959a) whilst components with low sedimentation constants have been found in patients in whom the histology was predominantly lymphoid in nature (Owen et al., 1959) .
In idiopathic cold-agglutinin haemolytic disease the anomalous components are mostly macroglobulins (Christenson, Dacie, Croucher, and Charlwood, 1957; Fudenberg and Kunkel, 1957) . In one such case, however, the amount of macroglobulin in the serum was within normal limits (Owen et al., 1959) , i.e., less than 5% of the total protein (Svedberg and Pedersen, 1940) . It may be noted that some of the macroglobulin normally in serum behaves as an a globulin while the remainder behaves as a y globulin (Wallenius, Trautman, Kunkel, and Franklin, 1957; Eriksen, 1958 (Fudenberg and Kunkel, 1957) . This suggests that the molecular size of an anomalous protein expresses the tendency of component units to aggregate and apparent heterogeneity on ultracentrifugation represents variable aggregation.
In amino-acid composition, myeloma and lymphoma proteins, though showing individual differences, closely resemble normal y globulin (Putnam, 1957 (Putnam, , 1958 . In only one instance has an amino-acid (hydroxy-proline) not detectable in y globulin been reported in an anomalous protein (Mandema et al., 1955) . Anomalous serum proteins likewise resemble normal y globulin in their N-terminal groups which are usually aspartyl or glutamyl or both. However, some myeloma proteins have been found to have either a leucyl or a phenylalanyl N-terminal grouping (Putnam, 1957 (Putnam, , 1958 neither of which has been detected in normal y globulin (Putnam, 1953; McFadden and Smith, 1953) .
The use of carbohydrate stains after paper electrophoresis of serum has indicated that anomalous serum proteins contain carbohydrate (Rice, 1954; Sonnet et al., 1955) . This has been confirmed by analysis of anomalous components isolated from serum, which have been found to contain hexose, hexosamine, and sialic acid (Lohss and Hillmann, 1953; Smith et al., 1955; MullerEberhard and Kunkel, 1956 ). The carbohydrate content of components of low molecular weight (S2 = 6-7 S) is lower than that of components of high molecular weight (S2 = 11-28 S); in both groups, the components with the mobilities in the ,8 globulin range contain more carbohydrate than those with mobilities in the y globulin range (Mtiller-Eberhard and Kunkel, 1956; Laurell et al., 1957 (Flemberg, 1948; Barr, Reader, and Wheeler, 1950; Putnam and Udin, 1953; Mackay et al., 1956) , lymphoma (Waldenstrom, 1944; Lucey et al., 1950; Abrams, Cohen, and Meyer, 1949; Mackay et al., 1957) i.e., less than 100 mg. /100 ml., have also been found in serum in a variety of diseases, including leukaemia, rheumatoid arthritis, bacterial endocarditis, nephrosis, and kala azar (Holmberg and Gronwall, 1942; Wertheimer and Stein, 1944; Lerner, Barnum, and Watson, 1947; Dreyfuss and Librach, 1952) . In some of these cases the isolated electrophoretic cryoglobulin was found to be electrophoretically homogeneous. In most, however, the amount was too small for the cryoglobulin to have appeared as a discrete electrophoretic component in the pattern obtained with whole serum.
Anomalous serum components in myelomatosis (Wuhrmann, Wunderly, and Haissig, 1950 ; Kunkel, Slater, and Good, 1951; Deutsch, Morton, and Kratochvil, 1956; Korngold and Lipari, 1956a) and in malignant lymphoma (Regniers et al., 1956; Korngold and van Leeuwen, 1957) Unlike any of the serum proteins so far characterized, Bence Jones proteins usually precipitate on heating at temperatures below 600 C. and redissolve, at least partially, on heating to 1000 C. Though presumably present in serum,, they are most readily detected in urine, often being present there in large amounts.
With boundary electrophoresis or zone electrophoresis on paper, Bence Jones protein in urine usually appears as a single peak or zone. The electrophoretic mobility, however, varies from patient to patient. In some cases traces of other proteins are present as a result of renal damage (Owen, 1957) . In occasional cases, the urinary electrophoretic pattern reveals the presence of two or more electrophoretic components (Putnam and Stelos, 1953; Berson and Yalow, 1957; Owen and Rider, 1958) .
In some instances, one of the components appears to be an anomalous serum component which has escaped from the circulation (Owen, 1957) . In others the Bence Jones protein appears to comprise more than one electrophoretic component. Electrophoresis in starch-gel has similarly shown electrophoretic heterogeneity in some Bence Jones proteins (Engle, Woods, and Pert, 1957; Flynn and Stow, 1958) .
Bence Jones proteins have usually a smaller molecular size than do most serum proteins which presumably allows their ready escape from the circulation into the urine. The sedimentation constant varies from case to case though most lie in the range SIO =2.5-4.5 S (Rundles, Cooper, and Willett, 1951; Putnam and Stelos, 1953) . They show marked individual differences in amino-acid composition (Putnam, 1957) . Thus methionine has been reported to be lacking in some Bence Jones proteins (Dent and Rose, 1949; Polonovski, Delbarre, and Levy, 1954) though present in others (Agren, 1952; Deutsch, 1955) .
Like anomalous serum components, Bence Jones proteins are antigenically related to normal y globulin (Korngold and Lipari, 1956b; Deutsch, Kratochvil, and Reif, 1955; Burtin, Hartmann, Fauvert, and Grabar, 1956 ). However, they too lack some of the antigenic determinants of normal y globulin.
As might be expected from these findings, Bence Jones proteins and anomalous serum components contain common antigenic determinants. Bence Jones proteins with different antigenic structures have been found in the same urine (Hektoen and Welker, 1940) .
Fornation and Fate of Anomalous Components
The frequent occurrence of anomalous serum and urinary protein components in myelomatosis and malignant lymphoma has led to the hypothesis, first put forward in respect of myelomatosis (Magnus-Levy, 1933) , that anomalous components are formed by myeloma or lymphoma cells. More direct evidence of the presence of anomalous components in myeloma or lymphoma tumour tissues has been obtained by several workers (Martin, 1947; Abrams et al., 1949; Lane, 1952;  Miller, Brown, Miller, and Eitelman, 1952; Buffa and Rappaport, 1957 Seybold, 1956; Vazquez, 1958; Curtain, 1959a) . Further, isotope incorporation studies have shown that myeloma cells are able to synthesize the anomalous components (Sonnet, 1957; . Supporting evidence comes from the discovery in mice of a transmissible plasmacytoma which is associated with an anomalous serum component (Potter, Fahey, and Pilgrim, 1957) . Whilst these findings shed light on the pathogenesis of anomalous components in patients with neoplastic conditions, they do not, of course, indicate the source of anomalous proteins in other conditions.
Labelling of anomalous serum proteins in myelomatosis with isotopes has shown that these components have a dynamic existence with halflives similar to those of other serum proteins (Hardy and Putnam, 1955; Putnam, Meyer, and Miyake, 1956; Osserman, Graff, Marshall, Lawlor, and Graff, 1957; Berson and Yalow, 1957) . Their exact fate, however, is unknown. Serial studies indicate that the concentration of an anomalous component in serum is frequently more or less constant over long periods in spite of the progression of the disease (Owen, Rider, and Newall. 1957) . Repeated venesections have likewise failed to influence the plasma level significantly (Barr et al., 1950; Soulier, 1950) . This suggests that the production and / or destruction mechanism is regulated by the concentration in the plasma. Individual differences in the amount of the anomalous component in plasma imply a different "setting" of the regulating mechanism in each case. Reiner and Stern (1953) (1) The Chemical Approach.-The aim with this approach has been to determine whether or not the anomalous component has some characteristic, e.g., amino acid, end-grouping, molecular size, not present in any of the normal components of serum. It has been claimed that hydroxyproline was present in an anomalous component, though absent from normal serum proteins (Mandema et al., 1955) . Clearly, however, failure to detect a protein with a particular feature in normal serum is of little significance since it is always possible that a more sensitive technique will succeed in this (Martin and Close, 1957 (Curtain, 1959b) .
Results of such experiments have suggested (Curtain, 1 Burnet (1957) to account for the production of antibodies. It should be noted, however, that individual antibodies in serum are widely distributed in the electrophoretic spectrum (Loveless and Cann, 1953; Laurell, 1955; Skom and Talmage, 1958) , unlike anomalous components which are mostly electrophoretically homogeneous.
Accordingly, each anomalous protein could be a component of y globulin which is recognized to comprise a large number of molecular species (Saifer and Corey, 1956 ). This would account for the physico-chemical affinities of y globulin and anomalous serum components. Moreover, there is evidence (Bing, 1940; Fagraeus, 1948; Coons, Leduc, and Connolly, 1955; Good, 1955; Ortega and Mellors, 1957 ) that y globulin is synthesized largely by plasma and lymphoid cells which are, at least morphologically, related to myeloma and lymphoma cells respectively. The selective proliferation of a single cell line required by this hypothesis and the consequent production of detectable amounts of a single protein is to be contrasted with the presumably non-selective proliferation of reticulo-endothelial cells, e.g., plasma cells, occurring in other conditions such as rheumatoid arthritis (Hayhoe and Smith, 1951) , infection (Fadem and McBirnie, 1950) , or neoplasia (Coste, Bourgeois, Delbarre, and Blatrix, 1948; Clark and Muirhead, 1954) . In these conditions there is usually no anomalous serum component though often a generalized hyperglobulinaemia.
The second possibility would involve somatic mutation and offers an alternative explanation for the apparently unlimited variation in the chemical and immunological nature of individual anomalous components. In considering the possibility that neoplasia represents the outcome of somatic mutation, Armitage and Doll (1954) have concluded that a series of changes must occur before the cell becomes frankly malignant. It is possible that occasionally one such change might cause the cell to produce the anomalous component (Mackay, 1956 ). This would explain the variable occurrence of anomalous components in patients suffering from the same disease, e.g., myelomatosis.
If this is correct, it would appear that this mutation usually occurs before that inducing frank malignancy, since the first appearance of anomalous serum components after the disease has become established has only rarely been recorded (Owen et al., 1957; see, however, Rundles et al., 1951; Martin and Close, 1957) . On the other hand, a change inducing the formation of an anomalous component could only become evident if sufficient cells of that particular line were present. This would occur when cell division became malignant. Possibly more benign cell division would result in the production of sufficient cells to form detectable amounts of anomalous components without producing anatomical evidence of neoplasia (cf. Case 2, Martin and Close, 1957) . This would explain apparently idiopathic cases, e.g., "essential" cryoglobulinaemia.
The possibility that anomalous components were the manifestation of virus infection was considered by Waldenstrom (1944) and also by Dent and Rose (1949) , who pointed out that certain Bence Jones proteins are similar chemically to the protein of tobacco mosaic virus in that they usually lack methionine. However, some Bence Jones proteins contain methionine. Moreover, evidence that myelomatosis or lymphoma is an infective condition has yet to be obtained. (Wiedermann, 1958) .
Whilst either of the first two possibilities provides an explanation for the association of anomalous components with neoplasia of the reticulo-endothelial system or elsewhere, the third possibility seems necessary to account for cases in which neoplasia are absent. The nature of the stimulus which would cause cells to increase the production of a protein to a detectable level or to produce a protein de novo is conjectural. The problem is similar to that posed by the production of antibodies.
In cases in which idiopathic cold-agglutinin haemolytic disease is associated with anomalous serum components the latter have been shown to have anti-erythrocytic properties. It seems likely, however, that their anti-erythrocytic activity is fortuitous and that the condition is not primarily one of auto-immunization. The concentration of anomalous components in serum is often much higher (g./100 ml.) than that usually assigned to antibodies. Further, the agglutinating properties of such proteins are greatest at non-physiological temperatures and they show little specificity towards the source of the erythrocytes whether from different individuals or different species (Dacie, 1954) . This is in contrast to the behaviour of warm agglutinins (Dacie and Cutbush, 1954) . As has been pointed out (Owen et al., 1959) , in Hashimoto's disease, which is much more certainly an auto-immune phenomenon, the serum contains auto-immune antibodies (Witebsky, Rose, and Shulman, 1958; Roitt, Doniach, Campbell, and Hudson, 1956 ), yet the serum electrophoretic pattern does not contain anomalous components, though the -y globulin peak is often increased (Cooke and Luxton, 1955; Doniach and Hudson, 1957) . The agglutinating activity of certain anomalous components is possibly analogous to the action of certain plant proteins in agglutinating erythrocytes (Landsteiner, 1936) , though some of the latter proteins, unlike anomalous serum components, show specificity towards erythrocytes of different ABO blood groups (Renkonen, 1948) .
It is of interest that the anti-erythrocytic activity of certain anomalous (macroglobulin) components disappears on dissociation of the molecule into smaller units (Fudenberg and Kunkel, 1957) . However, as these authors point out, the anti-erythrocytic activity is not simply due to the size of the molecule since most anomalous macroglobulin components do not have this property.
Lastly, the possibility that anomalous components, in some instances, constitute a congenital anomaly deserves consideration. Hereditary differences in the protein composition of serum have been revealed by starch-gel electrophoresis (Smithies, 1955 (Smithies, , 1958 . This could explain the presence of such components in the serum of apparently normal persons or of persons suffering from a disease not usually associated with anomalous components.
Pathological Effects
In patients with anomalous components, certain effects can be attributed to the production of anomalous components and to their presence in serum rather than to any primary disease process which may be present. These effects fall into two groups, those due to the consumption of materials in the synthesis of these components and those which are a direct consequence of the presence of the components in plasma.
The continued synthesis of anomalous components must involve utilization of amino-acids in competition with other tissues. Further, the urinary excretion of such components, e.g., Bence Jones proteins, involves loss of nitrogen from the body. Daily excretion rates of Bence Jones protein as high as 30 g. have been recorded (Hopkins and Savory, 1911; Dent and Rose, 1949) .
It should be noted, however, that whilst cachexia is common in the conditions in which anomalous components occur, e.g., myelomatosis, lymphoma, it is also prominent in other neop!astic conditions. Further comparison of mean survival times of patients with and without Bence Jones proteinuria have failed to reveal that this loss of nitrogen has a significant effect on survival time (Owen, 1958b) . Similarly, no difference has been found in the mean survival times of patients with severe hyperglobulinaemia and those with only moderate hyperglobulinaemia .
A reduced amount of normal y globulin has frequently been noted in patients with anomalous serum components (Adams, Alling, and Lawrence, 1949; Rundles et al., 1951; Snapper, Turner, and Moscovitz, 1953; Waldenstrom, 1954; Zinneman and Hall, 1954; Lawson, Stuart, Paull, Phillips, and Phillips, 1955; Porges, 1956; Firkin and Blackburn, 1958; Owen et al., 1959) Jim and Reinhard, 1956; Wall, 1956; Citron, 1957) in whom anomalous serum or urinary components were not present. This might suggest that competition is for space rather than for raw materials. On the other hand, many patients with lymphoma or leukaemia have normal or even increased serum y globulin levels (Rundles et al., 1951 ; Jim and Reinhard, 1956; Owen et al., 1956) .
The occurrence of a haemorrhagic tendency, manifested as bruising, bleeding from mucosal surfaces, or haemorrhagic retinitis, in association with anomalous serum components is well documented (Waldenstr6m, 1944; Craddock, Adams, and Figueroa, 1953; Frick, 1955; Long, Riopelle, Francoeur, Pare, Poirier, Georgesco, and Colpron, 1955; Jim and Steinkamp, 1956 ). This has been attributed either to a defective coagulation mechanism or to an effect of the anomalous serum components on capillary permeability (Waldenstrom, 1952) . Direct interaction of anomalous components with coagulation factors has been demonstrated in some cases (Henstell and Feinstein, 1957; Firkin, 1958) . Thrombocytopenia, however, is often present, and is presumably a contributory factor (Frick, 1955; Jim and Steinkamp, 1956; Mackay, 1956 ).
Cardiac failure in such patients has been attributed to a high blood viscosity resulting from the presence of anomalous components in plasma (Barr et al., 1950; McFarlane, Dovey, Slack, and Papastamatis, 1952) . A thrombotic tendency which, in some cases, may paradoxically accompany a haemorrhagic tendency, has also been attributed to a high blood viscosity (Frick, 1955) and is partly responsible for the retinitis present in some cases. Thrombosis of intracranial vessels is presumably also responsible in part for neurological and psychological symptoms, though there may be infiltration with neoplastic cells (Mackay, 1956) . Where the anomalous component is a cryoglobulin, blood viscosity may be greatly increased in exposed areas as a result of intravascular gellification or precipitation of the cryoglobulin. Local circulatory failure consequent on this gives rise to Raynaud's phenomenon and peripheral gangrene.
An increased erythrocyte sedimentation rate is usual, though not invariable (Owen and Rider, 1957) , in patients with anomalous serum components. Presumably the high sedimentation rate is due to interaction between anomalous components and erythrocytes.
Renal failure in myelomatosis is attributable to the deposition of protein within the kidney (Snapper et al., 1953 ; Allen, 1951) . Rarely protein as para-amyloid is deposited in the glomeruli. More commonly protein accumulates within the tubules. There is, however, little correlation between the degree of hyperglobulinaemia or proteinuria and the extent of renal impairment (Allen, 1951) . Amino-aciduria occurring in myelomatosis (Engle, 1956; Sirota and Hamerman, 1954 ) is perhaps due to direct competition between the tubular absorption of amino-acids and of anomalous components, especially Bence Jones proteins which presumably escape from the plasma more readily than anomalous serum components.
False positive Wassermann reactions have been noted in certain sera containing anomalous components (Long et al., 1955; Martin and Close, 1957; Zlotnick, 1958 ) whilst a related reaction (AICF) has been observed in other cases (Mackay and Gajdusek, 1958; Mackay, 1959) . Some sera with anomalous components have proved anticomplementary (Snapper et al., 1953; Volp6 et al., 1956) . It is not known, however, whether these reactions with complement are attributable directly to the presence of the anomalous component or, indirectly, to the underlying disease process.
CoDclusions
Anomalous serum -and urinary components occur most commonly in myelomatosis and lymphoma. They also occur occasionally in a number of other conditions. In a few cases, no histological evidence of disease can be obtained which suggests that such proteins are manifestations of a primary lesion at a biochemical level.
Certain morphological changes are probably secondary to the presence of the anomalous components.
In some of the conditions in which they have been found, incomplete data concerning occurrence of anomalous components make it yet impossible to assess their significance. In cases associated with malignant cell division, however, the production of anomalous components can best be attributed either to the selective proliferation of normal cells, i.e., cells which normally form the anomalous component in small amounts, or to the selective proliferation of abnormal cells, i.e., cells which have undergone a somatic mutation conferring on them the ability to produce the anomalous component.
The choice between these two possibilities depends largely on whether anomalous components are qualitatively normal or abnormal. As yet evidence does not allow a clear decision on this issue. Indeed, whilst it may be possible to prove that anomalous components are normally present in small amounts it is virtually impossible to prove that they are not.
